Sequences within Pr160gag-pol affecting the selective packaging of primer tRNA(Lys3) into HIV-1.
The selective packaging of the primer tRNA(Lys3) into HIV-1 particles is dependent upon the viral incorporation of the Pr160gag-pol precursor protein. In order to map a tRNA(Lys3) binding site within this precursor, we have studied the effects of mutations in Pr160gag-pol upon the selective incorporation of tRNA(Lys3). Many of these mutations were placed in a protease-negative HIV-1 proviral DNA to prevent viral protease degradation of the mutant Gag-Pol protein. C-terminal deletions of protease-negative Gag-Pol that removed the entire integrase sequence and the RNase H and connection subdomains of reverse transcriptase did not inhibit the incorporation of either the truncated Gag-Pol or the tRNA(Lys3), indicating that these regions are not required for tRNA(Lys3) binding. On the other hand, larger C-terminal deletions, which also remove the thumb subdomain sequence, did prevent tRNA(Lys3) packaging, without inhibiting viral incorporation of the truncated Gag-Pol, indicating a possible interaction between thumb subdomain sequences and tRNA(Lys3). While point mutations K249E, K249Q, and R307E in the primer grip region of the thumb subdomain have been reported to inhibit the in vitro interaction of mature reverse transcriptase with the anticodon loop of tRNA(Lys3), we find that these mutations do not inhibit tRNA(Lys3) packaging into the virus, which supports other work indicating that the anticodon loop of tRNA(Lys3) is not involved in interactions with Pr160gag-pol during tRNA(Lys3) packaging.
Khorchid
A
A
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
Javanbakht
H
H
Wise
S
S
Halwani
R
R
Parniak
M A
MA
Wainberg
M A
MA
Kleiman
L
L
D000595:Amino Acid Sequence; D000926:Anticodon / Q000235:genetics; D001665:Binding Sites; D015153:Blotting, Western; D015180:Electrophoresis, Gel, Two-Dimensional; D019302:HIV Envelope Protein gp160 / Q000032:analysis / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*; D019427:HIV Integrase / Q000032:analysis / Q000737:chemistry / Q000235:genetics; D016333:HIV Protease / Q000032:analysis / Q000737:chemistry / Q000235:genetics; D054303:HIV Reverse Transcriptase / Q000032:analysis / Q000737:chemistry / Q000235:genetics; D015497:HIV-1 / Q000235:genetics / Q000378:metabolism*; D008969:Molecular Sequence Data; D016254:Mutagenesis, Insertional / Q000235:genetics; D017354:Point Mutation / Q000235:genetics; D011498:Protein Precursors / Q000032:analysis / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D012313:RNA / Q000235:genetics / Q000378:metabolism*; D012357:RNA, Transfer, Lys / Q000235:genetics / Q000378:metabolism*; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism; D016914:Ribonuclease H / Q000032:analysis / Q000737:chemistry / Q000235:genetics; D017384:Sequence Deletion / Q000235:genetics; D013379:Substrate Specificity; D019065:Virus Assembly
D000926:Anticodon; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors; C034477:RNA primers; D012357:RNA, Transfer, Lys; D012367:RNA, Viral; D012313:RNA; D019427:HIV Integrase; D054303:HIV Reverse Transcriptase; D016914:Ribonuclease H; D016333:HIV Protease